CA3047992A1 - Azaindenoisoquinoline compounds and uses thereof - Google Patents

Azaindenoisoquinoline compounds and uses thereof Download PDF

Info

Publication number
CA3047992A1
CA3047992A1 CA3047992A CA3047992A CA3047992A1 CA 3047992 A1 CA3047992 A1 CA 3047992A1 CA 3047992 A CA3047992 A CA 3047992A CA 3047992 A CA3047992 A CA 3047992A CA 3047992 A1 CA3047992 A1 CA 3047992A1
Authority
CA
Canada
Prior art keywords
optionally substituted
substituents
compound
hydrogen
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3047992A
Other languages
English (en)
French (fr)
Inventor
Mark S. Cushman
Ping Wang
Yves George Pommier
Mohamed S. A. ELSAYED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
National Institutes of Health NIH
Original Assignee
Purdue Research Foundation
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, National Institutes of Health NIH filed Critical Purdue Research Foundation
Publication of CA3047992A1 publication Critical patent/CA3047992A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3047992A 2016-12-22 2017-12-19 Azaindenoisoquinoline compounds and uses thereof Pending CA3047992A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437777P 2016-12-22 2016-12-22
US62/437,777 2016-12-22
PCT/US2017/067206 WO2018118852A1 (en) 2016-12-22 2017-12-19 Azaindenoisoquinoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
CA3047992A1 true CA3047992A1 (en) 2018-06-28

Family

ID=62627773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047992A Pending CA3047992A1 (en) 2016-12-22 2017-12-19 Azaindenoisoquinoline compounds and uses thereof

Country Status (6)

Country Link
US (1) US10875860B2 (https=)
EP (1) EP3558993A4 (https=)
JP (1) JP7182548B2 (https=)
CN (1) CN110167936A (https=)
CA (1) CA3047992A1 (https=)
WO (1) WO2018118852A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023700A2 (en) * 2018-07-25 2020-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (Tdp1)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692410B2 (ja) 1988-08-30 1994-11-16 キッセイ薬品工業株式会社 新規なベンゾフロキノリン誘導体
CA2347100C (en) 1998-10-14 2010-12-14 Purdue Research Foundation Novel indenoisoquinolines as antineoplastic agents
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
EP1453812B1 (en) 2001-11-14 2008-08-20 Rutgers, The State University Cytotoxic agents
AU2002364953A1 (en) 2001-11-14 2003-06-17 Edmond J. Lavoie Topoisomerase poison agents
EP1646388A4 (en) 2003-05-12 2007-04-18 Purdue Research Foundation CYTOTOXIC INDENO AND ISOINDOLOISOCHINOLONE
EP1735281A4 (en) 2004-03-17 2009-11-04 Purdue Research Foundation Synthesis of Indinoisoquinoline Compounds and Their Use
US7495100B2 (en) 2004-05-07 2009-02-24 Purdue Research Foundation Synthesis of indenoisoquinolines
CA2629530C (en) 2005-11-14 2014-07-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services N-substituted indenoisoquinolines and syntheses thereof
US9399660B2 (en) 2005-11-14 2016-07-26 Purdue Research Foundation N-substituted indenoisoquinolines and syntheses thereof
WO2008076767A1 (en) 2006-12-13 2008-06-26 Purdue Research Foundation Chemotherapeutic flavonoids, and syntheses thereof
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
WO2009140467A1 (en) 2008-05-15 2009-11-19 Purdue Research Foundation Oxobenzindolizinoquinolines and uses thereof
WO2011094416A1 (en) 2010-01-27 2011-08-04 Purdue Research Foundation Substituted norindenoisoquinolines, syntheses thereof, and methods of use
US9073920B2 (en) 2010-08-17 2015-07-07 Purdue Research Foundation Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor
US9682990B2 (en) 2011-05-25 2017-06-20 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
US9328073B2 (en) 2011-05-25 2016-05-03 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
US8912213B2 (en) 2012-04-13 2014-12-16 Purdue Research Foundation Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors
US9034870B2 (en) 2012-07-13 2015-05-19 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
US8686146B2 (en) 2012-07-13 2014-04-01 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
EP2882714B1 (en) 2012-08-08 2019-11-13 Merck Patent GmbH (aza-)isoquinolinone derivatives
WO2015069766A1 (en) 2013-11-06 2015-05-14 Purdue Research Foundation Dupa-indenoisoquinoline conjugates

Also Published As

Publication number Publication date
JP2020506886A (ja) 2020-03-05
JP7182548B2 (ja) 2022-12-02
CN110167936A (zh) 2019-08-23
WO2018118852A1 (en) 2018-06-28
US10875860B2 (en) 2020-12-29
EP3558993A1 (en) 2019-10-30
US20200095243A1 (en) 2020-03-26
EP3558993A4 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
KR101586112B1 (ko) 카바졸 화합물 및 이 화합물의 치료학적 용도
KR20240040742A (ko) Kif18a 억제제로서의 화합물
CN112312899B (zh) 靶向癌症干细胞的癌症治疗
HK1225383A1 (zh) 二氮杂环庚烷衍生物及其用途
JP7245918B2 (ja) サルササポゲニン構造に基づく誘導体、医薬組成物及びその使用
EP4282864A1 (en) Cdk6/dyrk2 dual-target inhibitor, and preparation method therefor and use thereof
US6903133B2 (en) Anticancer compounds
EP3617204A1 (en) Indoleamine 2,3-dioxygenase inhibitor and application
CN112457308A (zh) 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
CN114507190B (zh) 一种氘代1,4-苯并二氮杂卓-2,5-二酮类化合物及其应用
US10875860B2 (en) Azaindenoisoquinoline compounds and uses thereof
WO2020247679A1 (en) Wdr5 inhibitors and modulators
KR20210123314A (ko) 불소 함유 치환 벤조티오펜 화합물, 그의 약학적 조성물 및 응용
CN117986269A (zh) 喜树碱衍生物及其制备方法和应用
CN104250250A (zh) 4-芳香胺基嘧啶类化合物及其抗肿瘤用途
KR102628246B1 (ko) 선택성 a2a 수용체 대항제
CN113717165A (zh) 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
US10759795B2 (en) Aza-A-ring indenoisoquinoline topoisomerase I poisons
EP3411377A1 (en) Prodrugs of anticancer agents indotecan and indimitecan
CN115806553A (zh) 杂环并内酰胺类衍生物、其制备方法及含有该衍生物的药物组合物在医药上的应用
CN120230084A (zh) 一种tdg抑制剂化合物及其用途
CN120574234A (zh) 具有透脑功能的高选择性parp1抑制剂
CN116462688A (zh) 芳香稠合环类衍生物及其制备方法和用途
WO2025077721A1 (en) Myt1 inhibitor based on fused thiazole or pyridine ring
WO2022006365A2 (en) Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240815

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241125

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250102

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250408

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250408

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250904

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250905

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251028

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251028

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251216

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260317